Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression
[ Vol. 19 , Issue. 1 ]
Liwei Lang, Austin Y. Shull and Yong Teng*Pages 17-25 (9)
Coordination between the amplification of the fibroblast growth factor FGF19, overexpression of its corresponding receptor FGFR4, and hyperactivation of the downstream transmembrane enzyme β-klotho has been found to play pivotal roles in mediating tumor development and progression. Aberrant FGF19-FGFR4 signaling has been implicated in driving specific tumorigenic events including cancer cell proliferation, apoptosis resistance, and metastasis by activating a myriad of downstream signaling cascades. As an attractive target, several strategies implemented to disrupt the FGF19-FGFR4 axis have been developed in recent years, and FGF19-FGFR4 binding inhibitors are being intensely evaluated for their clinical use in treating FGF19-FGFR4 implicated cancers. Based on the established work, this review aims to detail how the FGF19-FGFR4 signaling pathway plays a vital role in cancer progression and why disrupting communication between FGF19 and FGFR4 serves as a promising therapeutic strategy for disrupting cancer progression.
FGF19, FGFR4, β-klotho, cancer, target, drug development.
Department of Oral Biology, Augusta University, Augusta, GA 30912, Department of Biology, Presbyterian College, Clinton, SC 29325, Department of Oral Biology, Augusta University, Augusta, GA 30912
Read Full-Text article